Responses
Correspondence response
Response to: ‘Correspondence on ‘Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort’ by Micheroli et al’ by Huang et al
Compose a Response to This Article
Other responses
No responses have been published for this article.